Phase III squamous NSCLC survival readouts at ASCO for Keytruda, Tecentriq

Merck & Co. Inc. (NYSE:MRK) and Roche (SIX:ROG; OTCQX:RHHBY) each reported survival data from Phase III trials of their checkpoint inhibitors Keytruda pembrolizumab and Tecentriq atezolizumab, respectively, as first-line treatment of squamous non-small cell lung cancer (NSCLC). Both companies reported data in presentations at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

In the KEYNOTE-407

Read the full 564 word article

User Sign In